Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.373
-0.018 (-4.65%)
At close: Apr 28, 2026, 4:00 PM EDT
0.370
-0.003 (-0.80%)
Pre-market: Apr 29, 2026, 6:05 AM EDT
Femasys Employees
As of December 31, 2025, Femasys had 54 total employees, including 51 full-time and 3 part-time employees. The number of employees decreased by 17 or -23.94% compared to the previous year.
Employees
54
Change (1Y)
-17
Growth (1Y)
-23.94%
Revenue / Employee
$42,469
Profits / Employee
-$344,961
Market Cap
22.53M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 339 |
| Jin Medical International | 273 |
| Retractable Technologies | 227 |
| Bionano Genomics | 97 |
| Precision Optics Corporation | 90 |
| Ekso Bionics Holdings | 55 |
| Nephros | 36 |
| Zentek | 18 |
FEMY News
- 4 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 3 months ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 4 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 5 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 6 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 6 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire